Bioanalysis

Central Lab Market Projected to Reach $5.78 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 29, 2024
Genomics, Medicine, Growth, Health, Intelligence, ICON, Biomarker, Research, Bioanalysis, Artificial intelligence, ICON PLC, Anatomy, Drug, Clinical trial, Heart, Safety, Bangladesh Technical Education Board, Table, Government, Pharmaceutical industry

Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.

Key Points: 
  • Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.
  • The central lab market is witnessing substantial growth in the Americas, powered by increased clinical trial activities and a strong research infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Central Lab Market.
  • "Dive into the Central Lab Market Landscape: Explore 198 Pages of Insights, 388 Tables, and 24 Figures"

Central Lab Market Projected to Reach $5.78 billion by 2030 - Exclusive Report by 360iResearch

Retrieved on: 
Friday, March 29, 2024
Genomics, Medicine, Growth, Health, Intelligence, ICON, Biomarker, Research, Bioanalysis, Artificial intelligence, ICON PLC, Anatomy, Drug, Clinical trial, Heart, Safety, Bangladesh Technical Education Board, Table, Government, Pharmaceutical industry

Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.

Key Points: 
  • Central labs are overcoming these issues through technological innovation, strategic partnerships, and broadening their global reach to provide local services that meet international standards.
  • The central lab market is witnessing substantial growth in the Americas, powered by increased clinical trial activities and a strong research infrastructure.
  • We proudly unveil ThinkMi, a cutting-edge AI product designed to transform how businesses interact with the Central Lab Market.
  • "Dive into the Central Lab Market Landscape: Explore 198 Pages of Insights, 388 Tables, and 24 Figures"

QPS Continues UPLC-HRMS Expansion Into Europe to Support Gene Therapy and Protein Drug Development

Retrieved on: 
Thursday, December 14, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Chem, Tandem mass spectrometry, QPS, Chemistry, GLP, University of California, Berkeley, Peptide, Physikalisch-Technische Bundesanstalt, Diples, Multimedia, Daniel, LC-MS, Master of Science, Therapy, University of Kassel, Mass spectrometry, Drug discovery, University, Doctor of Philosophy, Biomarker, Oligonucleotide, UC, Drug development, LC-MS/MS, Fine chemical, Medtronic, Bioanalysis

QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.

Key Points: 
  • QPS announces an expanded and upgraded fleet of mass spectrometers, with the addition of a new TripleTOF® 6600+ for GLP quantitation in Groningen, The Netherlands.
  • This is a natural extension of 20+ years of supporting oligonucleotide drug development using LC-(HR)MS/MS in our Newark, Delaware, USA facility,” said Zamas Lam, PhD, Global Head of Bioanalytical (Mass Spec) & Preclinical Development, QPS LLC.
  • This has become an even higher priority with the explosion of work being done in the nucleic acid therapeutics and protein drug development arena,” said Daniel Schulz-Jander, MSc, PhD, Senior Director of Bioanalysis, QPS Netherlands.
  • With this expansion, this group now has all the necessary LC-MS and other chromatographic technology for PK/PD bioanalysis to support clients in drug discovery and development of gene therapies and protein drug development.

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023
Drug development, OpenBiome, PPD, MIT, AstraZeneca, MPH, McMaster University, MD, Medicinal chemistry, Doctor of Philosophy, Research, ChromeOS, Internal medicine, Growth, Pharmacy, Novartis, Innate immune system, Medicine, Bristol Myers Squibb, Amgen, Drug discovery, Molecular biology, Biomarker, Nobel Prize, United States Air Force Scientific Advisory Board, SAB, Harvard University, Medical device, Pharmaceutical industry, Physiology, Fluid dynamics, Gastroenterology, Ultragenyx, TATAA, Western University, Bioanalysis

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

TATAA Announces Formation of Scientific Advisory Board

Retrieved on: 
Tuesday, October 31, 2023
Drug development, OpenBiome, PPD, MIT, AstraZeneca, MPH, McMaster University, MD, Medicinal chemistry, Doctor of Philosophy, Research, ChromeOS, Internal medicine, Growth, Pharmacy, Novartis, Innate immune system, Medicine, Bristol Myers Squibb, Amgen, Drug discovery, Molecular biology, Biomarker, Nobel Prize, United States Air Force Scientific Advisory Board, SAB, Harvard University, Medical device, Pharmaceutical industry, Physiology, Fluid dynamics, Gastroenterology, Ultragenyx, TATAA, Western University, Bioanalysis

GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").

Key Points: 
  • GOTHENBURG, Sweden, Oct. 31, 2023 /PRNewswire/ -- TATAA Biocenter (the "Company" or "TATAA"), a leading global CRO for high-quality molecular analysis, announced the formation of its Scientific Advisory Board ("SAB").
  • "We are excited to have such a distinguished group of experts on our Scientific Advisory Board.
  • The Scientific Advisory Board demonstrates our commitment to delivering innovative solutions and exceptional services to our clients, and we look forward to working closely with them to achieve our goals."
  • said Dr. Sofia Adolfsson, Scientific Officer and Head of Bioinformatics at TATAA.

Quantitative Bioanalysis of Antibody-Drug Conjugates by Mass Spectrometry, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 24, 2023
Biomarker, Bioanalysis, LC-MS, ADC, Associate Director of National Intelligence and Chief Information Officer, PK, Antibody, Toxicity, Therapy, Drug development, Fine chemical

TORONTO, Oct. 24, 2023 /PRNewswire-PRWeb/ -- Discover a groundbreaking webinar delving into bioanalytical complexity, strategy and regulatory considerations when developing ADC therapeutics with a focus on developing and validating liquid chromatography-mass spectrometry (LC-MS) pharmacokinetics (PK) assays.

Key Points: 
  • In this free webinar, gain insights into the complexity, comprehensive strategy and regulatory considerations for bioanalysis in support of the development of drug-conjugated antibody (ADC).
  • Attendees will learn bioanalytical strategies for ADC drug development and how to apply the PK assay results to inform on ADC stability and dose selection.
  • Antibody-drug conjugates are a new and fast-growing class of targeted drugs consisting of "antibodies, cytotoxic drugs and linkers".
  • Join experts from Amador Bioscience , Meina Liang, Chief Technology Officer (CTO), President of Bioanalysis & Biomarkers; and Andrea Ngai, Associate Director, Bioanalysis & Biomarkers, for the live webinar on Wednesday, November 8, 2023, at 12pm EST (9am PST).

Bioanalytical Strategies for Gene Therapy: Bioanalysis of Lipid Nanoparticles Encapsulated Antisense Oligonucleotides, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Thursday, July 27, 2023
Tissue, Drug development, Gene, RX-250-LPN, Biotechnology, Gene editing, Oligonucleotide, Associate, Xtalk, Biomarker, Cell, ASO, Elisa's, R, LNP, HPLC, Fine chemical, Pharmaceutical industry, Bioanalysis

Toronto, July 27, 2023 /PRNewswire-PRWeb/ -- Emerging fields in healthcare, such as gene therapy, hold the key to unlocking new treatments for diseases. To provide greater insights into this burgeoning field, Rafiq Islam, VP of Bioanalysis and Biomarker at Amador Bioscience, and Margaret Costanzo, Associate Principal Scientist of Cell & Gene Therapy at Amador Bioscience, are set to lead a comprehensive and timely webinar on the critical topic of bioanalytical strategies for gene therapy.

Key Points: 
  • Toronto, July 27, 2023 /PRNewswire-PRWeb/ -- Emerging fields in healthcare, such as gene therapy, hold the key to unlocking new treatments for diseases.
  • This webinar, "Bioanalytical Strategies for Gene Therapy: Bioanalysis of Lipid Nanoparticles Encapsulated Antisense Oligonucleotides," aims to shed light on the sophisticated technologies required to deliver gene therapies effectively.
  • These encompass a range of oligonucleotides, with lipid nanoparticles (LPNs) playing a crucial role as carriers targeting specific cells and tissues.
  • This 60-minute session is your chance to stay abreast with the latest strategies and techniques that apply to the bioanalysis of gene therapies.

Pyxis Oncology Reports Financial Results for the Fiscal Year Ended December 31, 2022, and Provides Corporate Update

Retrieved on: 
Wednesday, March 22, 2023
TIP, Insurance, Abstract (summary), Common stock, Therapy, American Society of Clinical Oncology, Clinical trial, Research, Immunotherapy, ELISA, ASCO, Plasma, Patient, Cancer, Annual general meeting, ADC, Growth, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, Food, Pharmaceutical industry, Cryptocurrency, Bioanalysis

CAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today reported financial results for the full year ended December 31, 2022, and provided a corporate update.“Over the past year, our team has made significant progress in advancing PYX-201, our antibody-drug conjugate (ADC) product candidate, and PYX-106, our immunotherapy product candidate, into Phase 1 clinical trials,” said Lara S. Sullivan, M.D., President and Chief Executive Officer of Pyxis Oncology. “Our strong balance sheet gives us a cash runway into the first half of 2025 as we continue to advance these programs for patients. We anticipate preliminary data from both trials, including biomarker results and potential early signs of clinical activity, in late 2023 to early 2024.”

Key Points: 
  • “Our strong balance sheet gives us a cash runway into the first half of 2025 as we continue to advance these programs for patients.
  • Subject dosing is underway in the Phase 1 trial of PYX-201, known as PYX-201-101 .
  • Research and development expenses were $86.1 million for the year ended December 31, 2022, compared to $51.0 million for the year ended December 31, 2021.
  • General and administrative expenses were $37.4 million for the year ended December 31, 2022, compared to $18.7 million for the year ended December 31, 2021.

CMP Scientific Signs a Co-Marketing Agreement with Agilent to Advance Capillary Electrophoresis–Mass Spectrometry Solutions

Retrieved on: 
Tuesday, October 18, 2022
Consulting, Technology, Manufacturing, Professional Services, Health, General Health, Pharmaceutical, Other Technology, Research, Science, Chemicals, Plastics, Proteomics, Bioanalysis, Metabolomics, LC-MS, Biotechnology, Partnership, First American Scientific Corp., CMP, Agilent Technologies, Mab, CE-MS, CE, Pharmaceutical industry, Medical device, Fine chemical

CMP Scientific Corp., a leader in Capillary Electrophoresis-Mass Spectrometry (CE-MS) technologies, today announced that it has signed a global co-marketing agreement with Agilent Technologies to provide an integrated CE-MS solution to life science and pharmaceutical industry.

Key Points: 
  • CMP Scientific Corp., a leader in Capillary Electrophoresis-Mass Spectrometry (CE-MS) technologies, today announced that it has signed a global co-marketing agreement with Agilent Technologies to provide an integrated CE-MS solution to life science and pharmaceutical industry.
  • CMP Scientific develops, manufactures, and sells products and analytical instruments in life sciences, diagnostics, and applied markets.
  • CMP and Agilent will work together to implement new applications for the CE-MS system, which is a sensitive, alternative method to liquid chromatography-mass spectrometry (LC-MS) in mapping biological components.
  • For CMPs complete product line, please visit www.cmpscientific.com/products-and-services
    About CMP Scientific Corp: Founded in 2009, CMP is a global analytical instrument company with advanced, proprietary CE-MS technologies.

Global Preclinical CRO Market Report 2022: Increase in R&D Budget for Drug Development Presents Lucrative Opportunities - ResearchAndMarkets.com

Retrieved on: 
Tuesday, August 23, 2022
Health, General Health, Decision-making, Application, Research, Diabetes, Investment, Degenerative disease, Mergers and acquisitions, Royal Belfast Academical Institution, Strategic management, USD, Business Growth Fund, Value, CAGR, Customer support, Government, Use, Market share analysis, News, Gaps, Acquisition, Growth, Toxicology testing, Toxicology, Weakness, Infection, Global, Collaborative partnership, Neurological disorder, Fine chemical, Retail, Bioanalysis

Based on End-user, the market was studied across Biopharmaceutical Companies, Government and Academic Institutes, and Medical Device Companies.

Key Points: 
  • Based on End-user, the market was studied across Biopharmaceutical Companies, Government and Academic Institutes, and Medical Device Companies.
  • Based on Application, the market was studied across Cardiovascular Diseases, Central Nervous System Disorders, Diabetes, Immunological Disorders, Infectious Diseases, Oncology, and Respiratory Diseases.
  • Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa.
  • The United States is further studied across California, Florida, Illinois, Massachusetts, Minnesota, New Jersey, New York, Ohio, Pennsylvania, and Texas.